Alector (ALEC) Total Non-Current Liabilities (2018 - 2026)
Alector's (ALEC) quarterly Total Non-Current Liabilities came in at $210.8 million in Q2 2026, down 25.72% year-over-year from $283.8 million in Q2 2025, and down 7.45% quarter-over-quarter from $227.8 million in Q1 2026.
Analysis
Alector (ALEC) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Total Non-Current Liabilities for 9 consecutive years, with $210.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 25.72% year-over-year to $210.8 million in Q2 2026; TTM through Jun 2026 was $210.8 million, a 25.72% decrease from a year earlier, with the FY2025 full-year figure at $260.9 million, down 23.34% from the prior year.
- Total Non-Current Liabilities was $210.8 million for Q2 2026 at Alector, down from $227.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $686.8 million in Q1 2022 and troughed at $210.8 million in Q2 2026.
- A 5-year average of $427.6 million and a median of $437.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities jumped 223.37% in 2022 and plunged 32.25% in 2025, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $572.4 million in 2022, then slipped by 15.05% to $486.3 million in 2023, then sank by 30.03% to $340.3 million in 2024, then fell by 23.34% to $260.9 million in 2025, then decreased by 19.19% to $210.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $210.8 million (Q2 2026), $227.8 million (Q1 2026), and $260.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | 210.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 210.80 Mn |
| Mar 31, 2026 | 227.76 Mn |
| Dec 31, 2025 | 260.85 Mn |
| Sep 30, 2025 | 276.13 Mn |
| Jun 30, 2025 | 283.80 Mn |
| Mar 31, 2025 | 312.30 Mn |
| Dec 31, 2024 | 340.27 Mn |
| Sep 30, 2024 | 395.86 Mn |
| Jun 30, 2024 | 418.93 Mn |
| Mar 31, 2024 | 455.21 Mn |
| Dec 31, 2023 | 486.30 Mn |
| Sep 30, 2023 | 508.94 Mn |
| Jun 30, 2023 | 511.53 Mn |
| Mar 31, 2023 | 564.43 Mn |
| Dec 31, 2022 | 572.45 Mn |
| Sep 30, 2022 | 583.70 Mn |
| Jun 30, 2022 | 600.92 Mn |
| Mar 31, 2022 | 686.76 Mn |
| Dec 31, 2021 | 513.78 Mn |
| Sep 30, 2021 | 518.18 Mn |